Solving Clinical Trial Delays by Accelerating Patient Recruitment
CLINICAL TRIALS are the linchpin for bringing new medications to market, and they depend on patient participation. However, stalled patient recruitment is a significant, ongoing
CLINICAL TRIALS are the linchpin for bringing new medications to market, and they depend on patient participation. However, stalled patient recruitment is a significant, ongoing
Jeeva Clinical Trials is revolutionizing drug development by integrating AI and automated workflows into clinical trials, significantly reducing the time and cost of bringing treatments
In recent years, transformative strides in the treatment of sickle cell disease (SCD) have materialized with the FDA’s approval of groundbreaking cell-based gene therapies. Notably,
The recent Food and Drug Administration (FDA) approval of cell-based gene therapies for Sickle Cell Disease (SCD) marks a groundbreaking milestone in the field of
Abstract One of the main challenges in rare diseases is the unavailability of reliable estimates of prevalence and incidence. The lack of epidemiological data makes
Gender gaps, with consistent underrepresentation of females, present a substantial challenge in clinical research.(1) Achieving a balanced representation of both genders has proven exceedingly difficult,
NEW YORK, Feb. 6, 2024 /PRNewswire/ — Redwood Scientific Technologies Inc. (OTC: RSCI), (“Redwood” or “the Company”), a pioneering pharmaceutical company headquartered in New York,
In the fast-paced world of biopharmaceuticals, emerging and mid-market companies face significant challenges when bringing innovative drugs to market. One major obstacle is the costly
Gender gaps, with consistent underrepresentation of females, present a substantial challenge in clinical research.1 Achieving a balanced representation of both genders has proven exceedingly difficult,
Rare diseases affect only a few people in a given population but, collectively, they impact over 400 million people globally (3). It is estimated that
